ATE488499T1 - Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus - Google Patents
Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen darausInfo
- Publication number
- ATE488499T1 ATE488499T1 AT08788986T AT08788986T ATE488499T1 AT E488499 T1 ATE488499 T1 AT E488499T1 AT 08788986 T AT08788986 T AT 08788986T AT 08788986 T AT08788986 T AT 08788986T AT E488499 T1 ATE488499 T1 AT E488499T1
- Authority
- AT
- Austria
- Prior art keywords
- phenoxypyrrolidine
- derivative
- compositions
- phenoxy
- compound
- Prior art date
Links
- AUSRRRUBMHIEJD-UHFFFAOYSA-N 1-phenoxypyrrolidine Chemical class C1CCCN1OC1=CC=CC=C1 AUSRRRUBMHIEJD-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- MZYNHNDFHWNIIU-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]-1-[3-[2-(trifluoromethyl)phenoxy]pyrrolidin-1-yl]ethanone Chemical compound C1=CC(CO)=CC=C1OCC(=O)N1CC(OC=2C(=CC=CC=2)C(F)(F)F)CC1 MZYNHNDFHWNIIU-UHFFFAOYSA-N 0.000 abstract 1
- 108010087894 Fatty acid desaturases Proteins 0.000 abstract 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95459307P | 2007-08-08 | 2007-08-08 | |
| PCT/IB2008/002028 WO2009019566A1 (en) | 2007-08-08 | 2008-07-28 | Phenoxy-pyrrolidine derivative and its use and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE488499T1 true ATE488499T1 (de) | 2010-12-15 |
Family
ID=39870001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08788986T ATE488499T1 (de) | 2007-08-08 | 2008-07-28 | Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8242286B2 (de) |
| EP (1) | EP2173711B1 (de) |
| JP (2) | JP5239001B2 (de) |
| KR (1) | KR101189189B1 (de) |
| CN (2) | CN101821234B (de) |
| AT (1) | ATE488499T1 (de) |
| AU (1) | AU2008285255B2 (de) |
| BR (1) | BRPI0815048B8 (de) |
| CA (1) | CA2695664C (de) |
| DE (1) | DE602008003586D1 (de) |
| ES (1) | ES2352098T3 (de) |
| MX (1) | MX2010001485A (de) |
| RU (1) | RU2010107892A (de) |
| WO (1) | WO2009019566A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0815048B8 (pt) * | 2007-08-08 | 2021-05-25 | Graceway Pharmaceuticals Llc | derivados de fenóxi-pirrolidinas, seus usos e composições farmacêuticas |
| FR2948939B1 (fr) | 2009-08-05 | 2013-03-22 | Pf Medicament | Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine |
| FR2958935B1 (fr) * | 2010-04-19 | 2012-06-22 | Pf Medicament | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine |
| BR112012026875B1 (pt) | 2010-06-11 | 2018-12-04 | Avon Products, Inc. | método cosmético para melhorar a aprência da pele afetada pela celulilte e para reduzir recorrência de celulite em uma área previamente afetada e kit |
| US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
| US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US10405795B1 (en) | 2013-03-15 | 2019-09-10 | The Procter & Gamble Company | Methods of classifying periorbital dyschromia and systems therefor |
| WO2015019359A1 (en) * | 2013-08-08 | 2015-02-12 | Galderm Therapeutics Ltd. | Anti-acne compositions comprising bile acid-fatty acid conjugates |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| KR20170000657U (ko) | 2015-08-11 | 2017-02-21 | 김유호 | 골프연습기 |
| EP3463277A4 (de) * | 2016-06-06 | 2020-01-01 | GDD Therapeutics, LLC | Formulierungen für substituierte 3-pyrrolidine, zusammensetzungen damit und verwendungen davon |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| EP3566055B1 (de) | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Scd-hemmer zur behandlung von neurologischen erkrankungen |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2019183587A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2020154571A1 (en) | 2019-01-24 | 2020-07-30 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US20240189275A1 (en) * | 2021-02-19 | 2024-06-13 | Lipidio Pharmaceuticals, Inc. | Methods for treating non-alcoholic steatohepatitis with a scd-1 inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH432495A (de) * | 1964-02-04 | 1967-03-31 | Geigy Ag J R | Verfahren zur Herstellung neuer Aryloxyessigsäureamide |
| CA2067514A1 (en) | 1991-05-10 | 1992-11-11 | Sergiu Mircea Gorun | Manganese oligomer containing main group elements |
| US6338144B2 (en) | 1999-02-19 | 2002-01-08 | Sun Microsystems, Inc. | Computer system providing low skew clock signals to a synchronous memory unit |
| US20050119251A1 (en) | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
| MXPA06001202A (es) | 2003-07-29 | 2006-08-31 | Xenon Pharmaceuticals Inc | Derivados piridilo y su uso como agentes terapeuticos. |
| CA2533900A1 (en) | 2003-07-30 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| PL1648874T3 (pl) | 2003-07-30 | 2012-04-30 | Xenon Pharmaceuticals Inc | Pochodne piperazyny i ich zastosowanie jako środków leczniczych |
| US7456180B2 (en) | 2003-07-30 | 2008-11-25 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| HUP0401526A2 (en) * | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use |
| US20090118296A1 (en) * | 2005-07-20 | 2009-05-07 | Merck Frosst Canada Ltd. | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase |
| CA2654098A1 (en) * | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| BRPI0815048B8 (pt) | 2007-08-08 | 2021-05-25 | Graceway Pharmaceuticals Llc | derivados de fenóxi-pirrolidinas, seus usos e composições farmacêuticas |
-
2008
- 2008-07-28 BR BRPI0815048A patent/BRPI0815048B8/pt active IP Right Grant
- 2008-07-28 ES ES08788986T patent/ES2352098T3/es active Active
- 2008-07-28 AT AT08788986T patent/ATE488499T1/de not_active IP Right Cessation
- 2008-07-28 DE DE602008003586T patent/DE602008003586D1/de active Active
- 2008-07-28 KR KR1020107001820A patent/KR101189189B1/ko active Active
- 2008-07-28 CN CN200880111278.9A patent/CN101821234B/zh active Active
- 2008-07-28 EP EP08788986A patent/EP2173711B1/de active Active
- 2008-07-28 US US12/670,010 patent/US8242286B2/en active Active
- 2008-07-28 AU AU2008285255A patent/AU2008285255B2/en not_active Ceased
- 2008-07-28 MX MX2010001485A patent/MX2010001485A/es not_active Application Discontinuation
- 2008-07-28 JP JP2010519537A patent/JP5239001B2/ja active Active
- 2008-07-28 WO PCT/IB2008/002028 patent/WO2009019566A1/en not_active Ceased
- 2008-07-28 RU RU2010107892/04A patent/RU2010107892A/ru not_active Application Discontinuation
- 2008-07-28 CN CN201410216236.9A patent/CN104292144B/zh active Active
- 2008-07-28 CA CA2695664A patent/CA2695664C/en active Active
-
2012
- 2012-07-13 US US13/549,299 patent/US8524761B2/en active Active
-
2013
- 2013-03-05 JP JP2013043265A patent/JP5805119B2/ja active Active
- 2013-07-18 US US13/945,622 patent/US8980936B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009019566A1 (en) | 2009-02-12 |
| CN101821234B (zh) | 2014-06-25 |
| KR20100040878A (ko) | 2010-04-21 |
| BRPI0815048B1 (pt) | 2020-09-29 |
| CN104292144A (zh) | 2015-01-21 |
| KR101189189B1 (ko) | 2012-10-10 |
| ES2352098T3 (es) | 2011-02-15 |
| US8980936B2 (en) | 2015-03-17 |
| AU2008285255B2 (en) | 2012-09-27 |
| CA2695664C (en) | 2014-12-09 |
| EP2173711A1 (de) | 2010-04-14 |
| DE602008003586D1 (de) | 2010-12-30 |
| US20120277280A1 (en) | 2012-11-01 |
| CN104292144B (zh) | 2017-05-17 |
| JP2010535756A (ja) | 2010-11-25 |
| US20100247471A1 (en) | 2010-09-30 |
| RU2010107892A (ru) | 2011-09-27 |
| JP5239001B2 (ja) | 2013-07-17 |
| AU2008285255A1 (en) | 2009-02-12 |
| US8524761B2 (en) | 2013-09-03 |
| US8242286B2 (en) | 2012-08-14 |
| JP5805119B2 (ja) | 2015-11-04 |
| EP2173711B1 (de) | 2010-11-17 |
| BRPI0815048B8 (pt) | 2021-05-25 |
| US20140045911A1 (en) | 2014-02-13 |
| BRPI0815048A2 (pt) | 2016-04-05 |
| MX2010001485A (es) | 2010-06-01 |
| CA2695664A1 (en) | 2009-02-12 |
| CN101821234A (zh) | 2010-09-01 |
| JP2013100377A (ja) | 2013-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE488499T1 (de) | Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus | |
| ATE447559T1 (de) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen | |
| UA111725C2 (uk) | Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол | |
| EA201100049A1 (ru) | Органические соединения | |
| CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
| EA201001359A1 (ru) | Гетероциклические соединения в качестве ингибиторов cxcr2 | |
| CL2016001023A1 (es) | Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2. | |
| EA201070698A1 (ru) | Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты | |
| CL2011002781A1 (es) | Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer. | |
| UY33397A (es) | Forma sólida de un naftaleno carboxamida | |
| CY1116377T1 (el) | Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης | |
| EA201290255A1 (ru) | Способы и композиции для лечения рака | |
| SMT201300098B (it) | Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide | |
| ECSP11010830A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| EA201070039A1 (ru) | Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1 | |
| DE602008005141D1 (de) | 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase | |
| PE20081372A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[4-(7-ETIL-5H-PIRROLO[2,3-b]PIRAZIN-6-IL)-FENIL]-PROPAN-2-OL COMO INHIBIDOR DE QUINASA | |
| EA201170052A1 (ru) | Производные тиофена или тиазола и их применение как ингибиторов pi3k | |
| UA122520C2 (uk) | Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами | |
| EA201100093A1 (ru) | Тиадиазолилоксифениламидины и применение их в качестве фунгицидов | |
| UA106880C2 (uk) | Нові гербіциди | |
| EA201270253A1 (ru) | Производные n1-ацил-5-фторпиримидинона | |
| MA32788B1 (fr) | 1-(arylsulfonyl)-4-(piperazine-1-yl)-1h-benzimidazoles servant de ligands de la 5-hydroxytryptamine-6 | |
| NO20080265L (no) | 2-(1H-indolylsulfanyl)-arylaminderivater | |
| CL2009000076A1 (es) | Compuestos derivados de 4-(6-cloro-piridin-3-il)-5-(2-fluoro-fenil)-piridazina; procesos de preparacion de los mismos; composicion fungicida que los contienen; y uso de dichos compuestos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |